Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for Loa Loa Infection
NCT02644525Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in loiasis, sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2019; status: terminated.
02
Drugs
03
Conditions
loiasis
Beyond the preview
Go deeper on NCT02644525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644525.